Obesity and diet-related diseases have a significant negative impact on individual and public health outcomes, health care costs, and productivity. This effort ensures that Americans will have access to safe, affordable, and effective satiety modulators to control obesity. The Nutrition Based Satiety Modulation project aims to identify, characterize, and develop precision delivery nutrition platforms, beginning with testing generally recognized as safe (GRAS) compounds that confer satiety modulation/potentiation. Unlike recently developed pharmaceuticals such as GGLT2 inhibitors and GLP-1R agonists, VitaKey products will leverage natural mechanisms to modulate the body’s natural satiety responses to food intake. The goal is to formulate compounds that can be safely added to foods for broad distribution. The development and evaluation of natural, health-focused, nutrition-based satiety modulators could be scaled to provide an affordable and accessible solution for obesity treatment. If successful, this initiative has the potential to achieve GLP-1/GIP agonist effectiveness comparable to current pharmaceutical weight-loss treatments, without the associated side effects, and at significantly reduced cost. By developing these interventions, VitaKey will dramatically reduce many chronic diseases such as diabetes, cardiovascular disease, and cancer.